Zacks Small Cap Analysis – CTSO: CytoSorbents Expects Important Gross Margin Growth in 2024. – Model Slux
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT For the total 12 months 2023, complete revenues elevated roughly 5.0% to $36.3 million. Complete product gross sales had been $31.1 million, a rise of 6.0% from 2022. 2022 gross sales benefitted from $0.7 million in different non-CytoSorb gross sales and $0.3 million in … Read more